Andere Sprachen Immutep ADR Deutsche Boerse AG

Aktien

A2H8YL

US45257L1089

YP1A

Verzögert Deutsche Boerse AG Andere Börsenplätze 08:14:43 18.06.2024			% 5 Tage	% 1. Jan.
2,42 ^EUR	-3,20 %		0,00 %	+14,15 %

05.06.	Immutep schließt Aktienangebot ab	MT
03.06.	Immutep Limited kündigt klinische Zusammenarbeit mit Msd zur Evaluierung von Efti in Kombination mit Keytruda®? (Pembrolizumab) in pivotaler Phase Iii-Studie	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Immutep Completes Stock Offering	05.06.
Immutep : successfully completes institutional placement and institutional component of entitlement offer	05.06.
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	03.06.
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	03.06.
Immutep Raising AU$100 Million for Phase Three Trial	03.06.
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03.06.
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	03.06.
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15.05.
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15.05.
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15.05.
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	15.05.
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	03.05.
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02.05.
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02.05.
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02.05.
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30.04.
Immutep Quarterly Activities Report Q3 FY24	29.04.
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25.04.
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24.04.
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immutep ADR Deutsche Boerse AG

Aktien

A2H8YL

US45257L1089

YP1A

Andere Sprachen

Filter